Literature DB >> 23856325

NME1 suppression promotes growth, adhesion and implantation of endometrial stromal cells via Akt and MAPK/Erk1/2 signal pathways in the endometriotic milieu.

Ming-Qing Li1, Jun Shao, Yu-Han Meng, Jie Mei, Ying Wang, Hui Li, Li Zhang, Kai-Kai Chang, Xiao-Qiu Wang, Xiao-Yong Zhu, Da-Jin Li.   

Abstract

STUDY QUESTION: Is Nometastatic gene 23-H1 (NME1, also known as nm23-H1) involved in regulating the biological behavior of endometrial stromal cells (ESCs), and does it participate in the pathogenesis of endometriosis? SUMMARY ANSWER: NME1 suppression induces ESC dysfunction in the endometriotic milieu. WHAT IS KNOWN ALREADY: NME1 is a wide-spectrum tumor metastasis suppressor gene that plays an important role in suppressing the invasion and metastasis of tumor cells. STUDY DESIGN, SIZE, DURATION: An in vitro investigation of the effect of NME1 on the proliferation, adhesion and invasion of eutopic ESCs from patients with endometriosis. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Primary ESCs were prepared from 12 samples of ectopic endometrial tissue (6 peritoneal and 6 ovarian lesions), 18 samples of eutopic endometrial tissues (16 from women with ovarian and 2 from women with pelvic endometriomas) and 12 samples of normal endometrial tissue from women without endometriosis, after the tissues had been analyzed histologically. The growth, invasiveness and adhesion of ESCs were studied by the 5-bromo-2'-deoxyuridine cell proliferation assay and by the Matrigel invasion and adhesion assay. Additionally, the effects of NME1 on the activation or expression of related regulatory proteins were investigated by in-cell Western and flow cytometry assays. MAIN RESULTS AND THE ROLE OF CHANCE: Expression of NME1 in ESCs derived from eutopic or ectopic endometrium from women with endometriosis is lower than in ESCs from women without endometriosis. Estrogen could down-regulate NME1 expression in ESCs. Silencing NME1 in ESCs promoted the expression of proliferating cell nuclear antigen (PCNA), the anti-apoptotic molecule, survivin, and the adhesion-related molecules, integrin β1 and integrin ανβ3. Silencing NME1 also stimulated ESC proliferation, adhesion and invasion but these effects were inhibited by MAPK/Erk and/or Akt blockers. LIMITATIONS, REASONS FOR CAUTION: Further studies are needed to examine the regulatory mechanism of estrogen on NME1 expression of ESCs. WIDER IMPLICATIONS OF THE
FINDINGS: Abnormally low expression of NME1 in ESCs may be involved in the pathogenesis of endometriosis by up-regulating growth, adhesion and invasion of ESCs via activating the Akt and MAPK/Erk1/2 signal pathways. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by National Natural Science Foundation of China (NSFC) (31270969, 31101064 and 81270677) and Program for ZhouXue of Fudan University. None of the authors has any conflict of interest to declare.

Entities:  

Keywords:  NME1; adhesion; endometriosis; invasion; proliferation

Mesh:

Substances:

Year:  2013        PMID: 23856325     DOI: 10.1093/humrep/det248

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  15 in total

1.  Expression of focal adhesion kinase in endometrial stromal cells of women with endometriosis was adjusted by ovarian steroid hormones.

Authors:  Lin Mu; Yan-Yan Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis.

Authors:  Byung Gak Kim; Jung-Yoon Yoo; Tae Hoon Kim; Jung-Ho Shin; John F Langenheim; Susan D Ferguson; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Jae-Wook Jeong
Journal:  Hum Reprod       Date:  2015-03-06       Impact factor: 6.918

3.  L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner.

Authors:  Qing Wang; Li Wang; Jun Shao; Yan Wang; Li-Ping Jin; Da-Jin Li; Ming-Qing Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  Association between nm23 gene polymorphisms and the risk of endometriosis.

Authors:  X I Huang; Wei Zhao; Yan Li; Shan Kang
Journal:  Biomed Rep       Date:  2015-08-27

5.  Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells.

Authors:  Wen-Qing Shang; Jia-Jun Yu; Lei Zhu; Wen-Jie Zhou; Kai-Kai Chang; Qing Wang; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

6.  The metastasis suppressor NME1 inhibits melanoma cell motility via direct transcriptional induction of the integrin beta-3 gene.

Authors:  M Kathryn Leonard; Marián Novak; Devin Snyder; Grace Snow; Nidhi Pamidimukkala; Joseph R McCorkle; Xiuwei H Yang; David M Kaetzel
Journal:  Exp Cell Res       Date:  2018-11-17       Impact factor: 3.905

7.  TSLP induced by estrogen stimulates secretion of MCP-1 and IL-8 and growth of human endometrial stromal cells through JNK and NF-κB signal pathways.

Authors:  Kai-Kai Chang; Li-Bing Liu; Hui Li; Jie Mei; Jun Shao; Feng Xie; Ming-Qing Li; Da-Jin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8.

Authors:  Yan Guo; Ying Chen; Li-Bing Liu; Kai-Kai Chang; Hui Li; Ming-Qing Li; Jun Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

9.  NME1 suppression of endometrial stromal cells promotes angiogenesis in the endometriotic milieu via stimulating the secretion of IL-8 and VEGF.

Authors:  Kai-Kai Chang; Li-Bing Liu; Li-Ping Jin; Yu-Han Meng; Jun Shao; Ying Wang; Jie Mei; Ming-Qing Li; Da-Jin Li
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

10.  Metastasis suppressor NME1 regulates melanoma cell morphology, self-adhesion and motility via induction of fibronectin expression.

Authors:  Marián Novak; Mary Kathryn Leonard; Xiuwei H Yang; Anjan Kowluru; Alexey M Belkin; David M Kaetzel
Journal:  Exp Dermatol       Date:  2015-04-27       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.